Sanofi and Regeneron have announced that Dupixent has met all of its goals in a phase 3 trial studying the treatment in children aged 6 months to 5 years old with moderate-to-severe atopic dermatitis, making it the only biologic drug with positive data in patients that young.

The study, which has 162 children enrolled, found that Dupixent paired with standard of care, low-potency topical corticosteroids (TCS), reduced overall disease severity and improved skin clearance, itch and health-related quality of life measures at 16 weeks compared to just TCS alone.

Click here to read the entire article.